Doctor Fabio Dardi

Doctor Fabio Dardi

Institute of Cardiology, Bologna (Italy)

Fabio Dardi is graduated MD cum laude at the Alma Mater Studiorum University of Bologna (UNIBO) and attended the Postgraduate Specialization Schools of Cardiology at UNIBO. He attended the school of Excellence “Collegio Superiore” of UNIBO and is now in the Cardio Nephro Thoracic Sciences PhD program at the Department of Experimental, Diagnostic and Specialty Medicine (DIMES) of the UNIBO. He has specific competence in Pulmonary Vascular Disease and haemodynamic invasive evaluation of lung circulation acquired in the pulmonary vascular disease centre of Bologna. He is also Tutor of the International Master’s Degree in Pulmonary Vascular Diseases of the DIMES-UNIBO and has been recently nominated scientific board secretariat of the WSPH Association.

Presentations

Short term effect of Selexipag in comparison to parenteral prostacyclin analogues in pulmonary arterial hypertension patients started on double-combination therapy with ERA and PDE-5 inhibitors

Event: ESC Congress 2020

Topic: Pharmacotherapy

Session: Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure ePosters

Access

Prognostic value of stroke volume index in patients with pulmonary arterial hypertension at intermediate risk

Event: ESC Congress 2019

Topic: Epidemiology, Prognosis, Outcome

Session: Chronic venous thromboembolism

Access

A new score to differentiate idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction

Event: ESC Congress 2018

Topic: Pulmonary Hypertension

Session: Right heart failure in pulmonary hypertension

Access

Comparative outcome of incident patients with pulmonary hypertension due to lung disease according with the haemodynamic classification of the 2015 ESC-ERS pulmonary hypertension guidelines

Event: ESC Congress 2016

Topic: Chronic pulmonary hypertension

Session: Chronic pulmonary hypertension

Access

Doctor Fabio Dardi

Biography

Contributor content

Short term effect of Selexipag in comparison to parenteral prostacyclin analogues in pulmonary arterial hypertension patients started on double-combination therapy with ERA and PDE-5 inhibitors

Prognostic value of stroke volume index in patients with pulmonary arterial hypertension at intermediate risk

A new score to differentiate idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction

Comparative outcome of incident patients with pulmonary hypertension due to lung disease according with the haemodynamic classification of the 2015 ESC-ERS pulmonary hypertension guidelines

ESC 365 is supported by